Home Search
ar101 - search results
If you're not happy with the results, please do another search
Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food...
“In-licensing AIMab7195 demonstrates our commitment to enriching our pipeline and strengthening Aimmune’s global leadership in the evolving therapeutic landscape of food allergy treatments.”
FDA Approves Aimmune’s PALFORZIA as First Treatment for Peanut Allergy
Palforzia is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut.
AAAAI Addresses What Patients and Their Families Need to Know About Oral Immunotherapy (OIT)
As the FDA moves closer to approving the first food allergy treatment, the AAAAI seeks to help patients and their families understand the realities surrounding OIT.
FAQ for Palforzia, the First FDA Approved Therapy for Food Allergy
What it is, what it treats, who it is for, how it is used, et al.
Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for Egg Allergy
AR201 is the second development program that Aimmune is advancing to phase 2 using its Characterized Oral Desensitization ImmunoTherapy (CODIT™) platform.
Asthma and Allergy Foundation of America Responds to Premature ICER Review of New Peanut...
The AAFA addresses concerns
regarding the Final Evidence Report released by the ICER.
ICER’s Final Report on Peanut Allergy Treatments: Clinical Evidence Does Not Yet Demonstrate That...
The report evaluates Viaskin® Peanut and AR101, as well as non-commercialized oral immunotherapy (OIT).
Asthma and Allergy Foundation of America Elevates Patient Voice in ICER Review of New...
Affirms Burden of Food Allergies on Families, Patients, and Caregivers.
Joint Statement on Peanut Allergy Therapy Review
Organizations representing patients and allergists urge ICER to adopt a more patient-driven approach to assessing immunotherapies for peanut allergy.
Study: Over Half of Teens with Peanut Allergy Visited the ER, Over One-Third Required...
4 in 10 Teens believe they have a great or very great chance or certainty of dying from accidental exposure.
Established in 2011, SnackSafely.com provides straightforward, actionable information to help improve the lives of the estimated 32 million people in the US suffering with food allergies.
We strive to eliminate anaphylaxis by leveraging our on-line properties to educate, advocate, and connect the allergic community with products and services that help toward achieving this goal.
Our blog covers topics of interest to the food allergy community including news reports; ongoing research, clinical studies, trials and progress toward treatment and cure; general advocacy; and advice regarding food safety and school policies.
Please see our Terms of Service and Privacy Policy.
Copyright ©2011-2024 SnackSafely.com, Inc — All rights reserved